In addition to enhancing the apoptotic effects of the combined α-TOS and TRAIL treatment, α-TOS has been shown to increase the growth inhibitory effects of cisplatin, tamoxifen and decaprazine in melanoma cells [41] and parotid acinar carcinoma cells [42], as well as those of adriamycin in prostate carcinoma cells [43] and those of doxorubicin in leukemia cells [44]. Here, TNFSF10 is linked to melanoma.